Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

NCT06980623 · Active, not recruiting

Last updated 2026-05-28

This clinical trial compares two medications, tirzepatide and semaglutide, in adults with type 2 diabetes and heart failure to see how they affect hospitalizations for heart failure and overall survival.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 26,000 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-01 · est. completion 2026-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06980623 ↗

Description as written by the study sponsor.

This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.

Treatments tested

Tirzepatide Drug

Exposure group
Semaglutide Drug

Referent group

Main thing measured	Hospitalization for heart failure and all-cause mortality
Sponsor	Brigham and Women's Hospital
Conditions studied	Type 2 Diabetes, Heart Failure
GLP-1 drugs	semaglutide, tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06980623 ↗